Clinical Observation Of Yiqi Tuodu Therapy On Chronic Prostatitis Of Qi Deficiency And Toxin Stagnation Type

Objective In this study,we investigated the safety and clinical efficacy of prostate toroxin formula in the treatment of patients with chronic prostatitis(Qi deficiency and toxin stagnation syndrome),and also observed the changes of white blood celland lecithin body counts in prostatic fluid before and after the treatment,which may provide a certain reference for the treatment of chronic prostatitis by preqi toroxin method based on the theory of " Treating Chronic Prostatitis from sarcosis ".Methods This study used a self controlled research method and included 118 cases,who had taken prostatic torrotoxin formula for 4 consecutive weeks.The data of National Institutes of Health Chronic Prostatitis Symptom Index(NIH-CPSI),white blood cells in prostatic fluid,and lecithin bodies count were observed and recorded before and after treatment,respectively,and the statistical and analytical data were thus concluded.Results A total of 118 patients were included,8 cases were exfoliated,4 cases were excluded,and 106 cases were finally completed.1.Clinical cure after 4 weeks of treatment was observed in 9 cases,29 cases of marked effect,58 cases of effectiveness and 10 cases of ineffectiveness,with an overall response rate of 90.6%.2.The total NIH-CPSI scores,pain symptom scores,urinary symptom scores,and quality of life scores,as well as the white blood cell and lecithin body count levels in the prostatic fluid,were improved to various degrees after treatment,with all measures showing significant differences(P<0.05)compared with those before treatment;3.Effect of distribution of pretreatment patient data on efficacy: the comparison of efficacy among different age groups,between different disease duration groups,between groups of pretreatment symptom severity,between groups of pretreatment chronic prostatitis type IIIA and IIIB classification,between groups of different white blood cell count in prostatic fluid,and between groups of no lecithin body count before treatment showed no statistical significance(P>0.05).Conclusions1.Treatment of chronic prostatitis(Qi deficiency and toxin stagnation syndrome)with a prostate toroxin formula based on the ""theory of curing chronic prostatitis from sarcore "is highly effective in reducing NIH-CPSI scores,relieving pain symptoms and voiding symptoms due to chronic prostatitis,improving white blood cell and lecithin body counts in the prostatic fluid,and improving patient quality of life.2.The clinical efficacy of tofacitinib,a treatment for chronic prostatitis due to Qi deficiency,is not affected by the patient’s age,disease course,severity of symptoms before treatment,the results of typing chronic prostatitis type III A and III B before treatment,the results of leukocyte and lecithin body counts in the prostatic fluid before treatment,and there are no serious adverse effects,with a certain safety profile.